Subu Nambi

“As we think about Oncology Volume Guide, could you give us some puts and takes on the 50% guide raise? Is this largely from reveal in metastatic stage? And how is per patient testing cadence looking today?”

“You ungated volumes mainly for share gains and to push growth. What did you see in 1Q from like a competitive VIN perspective to reinforce that strategy is working?”

“One of the leading players in the rare disease market has had some challenges with reimbursement and mix. is this dynamic relevant for you? And then bigger picture, how is Zenith ramping and how are you differentiating there?”

“Frank, you mentioned M&A. Is that something you're looking at in your term? Can you just walk us through the factors you're considering when evaluating targets and your criteria there?”